Segulah Venture AB acquires shares in Senzime AB

Segulah Venture AB has entered into an agreement to acquire 2,500,000 shares in Senzime AB, by means of a directed equity issue. Senzime develops unique medical devices that enable patients’ biochemical and physiological processes to be monitored before, during, and after surgery.

The company’s solutions aim to ensure maximum patient benefit, reduce surgical complications, and cut healthcare costs. Senzime operates in growing markets, with Europe and the US alone currently valued at over SEK 10 billion.

Senzime stock is listed on NASDAQ Stockholm First North

For additional information, please contact
Lennart Kalén, Chairman of Segulah Venture AB, +46 70 536 26 00.